Scrip100: Indian firms up R&D spend, ascend value chain
This article was originally published in Scrip
The R&D spends of a clutch of frontline Indian firms have seen a significant uptick over the past few years, seemingly in line with their growing emphasis on complex therapy and limited competition areas as well as the efforts of some to make a mark in the biosimilars space.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.